India, Aug. 21 -- Shares of Protagenic Therapeutics, Inc. (PTIX) more than doubled on Thursday morning, after the biopharmaceutical company announced progress in its clinical trial for PT00114, a therapy targeting stress and mood disorders.
PTIX is currently trading at $4.96, up $2.68 or 117.56%, on the Nasdaq. The stock opened at $3.64, sharply higher than its previous close of $2.28. Trading volume was 60.9 million shares, far surpassing the company's average daily volume of 204,888 shares.
Protagenic revealed that all study subjects in the multiple-dose portion of its ongoing Phase 1 trial of PT00114 have received their first injections. The company expects dosing to be completed by the end of August, with topline safety results antici...